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Mutations in the Mitochondrial Seryl-tRNA Synthetase
Cause Hyperuricemia, Pulmonary Hypertension, Renal
Failure in Infancy and Alkalosis, HUPRA Syndrome
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An uncharacterized multisystemic mitochondrial cytopathy was diagnosed in two infants from consanguineous Palestinian kindred
living in a single village. The most significant clinical findings were tubulopathy (hyperuricemia, metabolic alkalosis), pulmonary
hypertension, and progressive renal failure in infancy (HUPRA syndrome). Analysis of the consanguineous pedigree suggested that
the causative mutation is in the nuclear DNA. By using genome-wide SNP homozygosity analysis, we identified a homozygous
identity-by-descent region on chromosome 19 and detected the pathogenic mutation c.1169A>G (p.Asp390Gly) in SARS2, encoding
the mitochondrial seryl-tRNA synthetase. The same homozygous mutation was later identified in a third infant with HUPRA syndrome.
The carrier rate of this mutation among inhabitants of this Palestinian isolate was found to be 1:15. The mature enzyme catalyzes the
ligation of serine to two mitochondrial tRNA isoacceptors: tRNASerAGY and tRNA
Ser
UCN. Analysis of amino acylation of the two target
tRNAs, extracted from immortalized peripheral lymphocytes derived from two patients, revealed that the p.Asp390Gly mutation signif-
icantly impacts on the acylation of tRNASerAGY but probably not that of tRNA
Ser
UCN. Marked decrease in the expression of the nonacy-
lated transcript and the complete absence of the acylated tRNASerAGY suggest that this mutation leads to significant loss of function and
that the uncharged transcripts undergo degradation.Progressive renal failure in infancy may result from
a number of etiologies including congenital anomalies of
the kidneys and urinary tract, ciliopathies (whether syn-
dromic or isolated renal disease), and congenital nephrotic
syndrome. Acquired multisystemic diseases, such as vascu-
litides, are uncommon at this age group. Mitochondrial
cytopathies are among the rare syndromes that manifest
in infancy and result in multiorgan disease. The most
common renal phenotype of mitochondrial cytopathy is
tubulopathy (Fanconi and Bartter-like syndromes as well
as renal tubular acidosis), but tubulo-interstitial disease
and nephrotic syndrome resulting from focal segmental
glomerulosclerosis have also been described.1,2
We investigated three infants of Palestinian descent who
presented with a multisystem disease in infancy. Two
infants (F1:III-1 and F1:III-6, Figure 1) were included in
the mapping of the gene, which, in its mutated form, is
responsible for the disease. The third child (F2:II-2) was
diagnosed after the completion of the genetic study.
Infants F1:III-1 and F1:III-6 belong to a consanguineous
kindred of Palestinian descent from the Greater Jerusalem
area (Figure 1). The nonconsanguineous parents F2:I-1 and
F2:I-2 are, to the best of their knowledge, unrelated to that
kindred but live in the same village. All affected individuals
were born prematurely and presented during infancy with
a multiorgan disease including kidney involvement, man-
ifesting with hyperuricemia, hypochloremic metabolic
alkalosis, progressive renal failure, and primary pulmonary
hypertension, collectively designated HUPRA syndrome.1Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem 9
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The AmericaThey all experienced feeding difficulties and develop-
mental delay. The clinical characteristics of patients with
the HUPRA syndrome are summarized in Table 1.
Patient F1:III-1
A4-month-old babyboy, the first child of nonconsanguine-
ous parents of Palestinian origin, was referred to our emer-
gencydepartmentbecause of acute bronchiolitis and failure
to thrive (FTT). Medical history was significant for prema-
ture birth at 34 weeks gestation, with an uneventful
neonatal course. Routine blood tests revealed renal failure
(serum creatinine, 0.99 mg/dl [age-appropriate normal
range (N), 0.2–0.4 mg/dl]; BUN, 44 mg/dl [N, 5–18 mg/dl];
estimated creatinine clearance of 29 ml/min/1.73 m2
[N, 39–114 ml/min/1.73 m2]), anemia (Hb, 9 g/dl [N >
10.5 g/dl]), and hyperuricemia (13.8 mg/dl [N, 2.4–
6.4 mg/dl]). Urinalysis demonstrated specific gravity of
1.010,mildproteinuria (protein/creatinineratio,1.26mg/mg
[N < 0.5 mg/mg]), and unrevealing cellular sediment.
Blood pressure was mildly elevated (115/60 mmHg [95th
percentile 115/60]) with borderline left ventricular hyper-
trophy on echocardiography. Abdominal ultrasound
showed normal sized kidneys with hyperechogenic appear-
ance. Because renal failure persisted after fluid replacement
therapy and recovery from the respiratory illness, a kidney
biopsy was performed. Renal histology showed immature
glomeruli, consistent with his age, which were otherwise
normal. Various tubulo-interstitial changes were noted
including dedifferentiated, atrophic tubules with thick1031, Israel; 2Institute of Medical Genetics, Shaare Zedek Medical Center,
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Figure 1. Implementation of SNP Microarray Analysis for the Identification of Mutation in SARS2
(A) Pedigrees of the families. DNA samples from individuals marked with asterisk were analyzed for the c.1169A>Gmutation in SARS2.
(B) Homozygosity mapping of DNA derived from patients F1:III-1 and F1:III-6. Detection of a common homozygous region on chromo-
some 19 by Genotyping Console (left) and KinSNP (right) software. SARS2 is located at the very end of the shared fragment.basement membrane or tubules that were completely
denuded. Hyperplastic arteriolitis was found in the intersti-
tium. Immunofluorescent staining of immunoglobulins
and components of the complement system was negative.
During the ensuing weeks, he developed moderate poly-
uria (urine output 4 ml/Kg/d) with salt wasting resulting in
hyponatremia (116 mEq/l [N, 133–146 mEq/l]), which
required supplementation. Azotemiawas always dispropor-
tionate to serum creatinine levels and hyperuricemia was
associated with decreased fractional excretion of uric acid
(FeUA, 5.7% [N> 7%]). Hypochloremicmetabolic alkalosis
persisted (32mEq/L [N, 16–24mEq/l]) in the face ofmoder-
ately elevated blood lactate concentrations (5–7 mmole/l
[N, 0.5–2.4mmol/l]) and despite worsening renal function.
Hypomagnesemia (0.9 mg/dl [N, 1.58–2.4 mg/dl]) and
elevated fractional excretion of magnesium (FeMg, 12.8%
[N < 5%]) were also noted. Additional characteristics of
his multiorgan disease included thrombocytopenia and
leukopenia with normal bone marrow examination, dia-
betes mellitus, hypotonia, global developmental delay,
and ongoing FTT. Liver function tests were within normal
limits and brain ultrasound was also normal. At 11 months
of age, he developed hypoxia resulting from primary
pulmonary hypertension (estimated pulmonary pressure
60 mmHg). He reached end-stage renal failure and chronic
peritoneal dialysis was initiated.
Metabolic workup showed high blood and CSF lactate
levels (10.2 mmol/l [N, 0.5–2.4 mmol/l] and 8.9 mmol/l194 The American Journal of Human Genetics 88, 193–200, February[N, 0.8–2.2 mmol/l], respectively) and increased serum
alanine concentration (1029 mM [N < 547 mM]). Muscle
biopsy demonstrated significant variations in fiber size,
consistent with type 2 fiber atrophy. Immunohistochem-
ical staining for cytochtome C oxidase (COX) and succi-
nate dehydrogenase (SDH) showed COX deficiency and
normal SDH in a number of the muscle fibers. No ragged
red fibers were identified on Gomori stain. On electron
microscopy some fibers were shown to have enlargedmito-
chondria. Re-evaluation of the electron microscopy of the
renal tissue demonstrated that a portion of the tubular
epithelial cells contained markedly enlarged mitochondria
with paracrystalline lesions (Figure 2), as previously
reported in conjunction with mitochondrial cytopathies.
His overall medical condition gradually deteriorated and
he succumbed to multiorgan failure at 14 months of age.
The parents subsequently had two healthy male offspring.
Patient F1:III-6
A 7-month-old baby girl was admitted to the hospital
because of recurrent vomiting and FTT. She was the third
child of healthy consanguineous parents of Palestinian
descent. She was born prematurely at 27 weeks of gestation
(birth weight 1080 g) and had an uneventful neonatal
course, except for mild metabolic alkalosis (serum bicar-
bonate 26–29.5 mEq/L, venous pCO2 43–45 mmHg).
Upon admission she weighed 3350 g (<3rd percentile).
Vital signs were normal. Physical examination was11, 2011
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Hypomagnesemia þ þ þ
High FeMg þ þ þ
Progressive renal failure þ þ þ
Extrarenal Manifestations
Prematurity þ þ þ
Pulmonary hypertension þ þ þ
Elevated serum lactate þ þ þ




Diabetes mellitus þ 5 þ
Pancytopenia þ - -
Abbreviations: FeUA, fractional excretion of uric acid; FeMg, fractional excre-
tion of magnesium; ND, not determined; plus andminus signs, stress hypergly-
cemia.unremarkable except for severe cachexia. Laboratory tests
were significant for leukopenia (WBC, 2100/mm3) and
anemia (Hb, 4.8 g/dl), salt wasting resulting in hyponatre-Figure 2. Electron Micrograph of Renal Tissue Obtained from
Patient F1:III-1
Abnormal enlarged mitochondria with paracrystalline inclusions
in a portion of the tubular epithelial cells (red arrows). Normal
mitochondrion is marked in a blue arrow.
The Americamia (124 mEq/L), renal failure (BUN, 87 mg/dl; creatinine,
1.14 mg/dl; estimated creatinine clearance of 22 ml/min/
1.73 m2), and metabolic alkalosis (pH 7.48; bicarbonate,
30 mEq/L; pCO2, 39 mmHg) with elevated blood lactate
(5.54 mmol/L). She was also noted to have marked hyper-
uricemia (26.8 mg/dl) associated with decreased FeUA
(<5.0%) and increased urinary magnesium leak leading
to hypomagnesemia (1.2 mg/dl).
During her hospital stay she developed systemic and
pulmonary hypertension with biventricular hypertrophy,
on echocardiography, and estimated pulmonary pressure
of 67/25 that partially responded to sildenafil. Addition-
ally, she suffered from global developmental delay. Her
renal function had gradually deteriorated and she experi-
enced occasional stress hyperglycemia (324 mg/dl). She
died at 10 months of age because of respiratory insuffi-
ciency.
Patient F2:II-2
A female baby who was born at 27 weeks gestation to
apparently nonconsanguineous parents of Palestinian
origin had an uneventful neonatal course. One year earlier,
her mother gave birth to a baby girl, also at 27 weeks
gestation, who suffered from pulmonary hypertension
and died of respiratory failure at the age of 39 days. She
also had moderate renal failure. At 4 months of age, our
patient was referred to another hospital because of poor
feeding and failure to thrive, and she developed a sepsis-
like episode with hemodynamic shock and severe meta-
bolic acidosis requiring mechanical ventilation and
vasopressor support. Blood and CSF cultures were negative.
After recovering from the acute episode, she was found to
have several medical problems. (1) Severe pulmonary
hypertension and right ventricular hypertrophy, detected
by echocardiography, which partially responded to
sildenafil. (2) Renal failure (estimated creatinine clearance,
31 ml/min/1.73 m2) associated with normal sized hyper-
echogenic kidneys. (3) Electrolyte imbalance: hyperuri-
cemia (14.1 mg/dl) with low FeUA, urinary magnesium
leak resulting in hypomagnesemia (0.97 mg/dl), salt
wasting leading to hyponatremia (122 mEq/l), metabolic
alkalosis (bicarbonate 29.4 mEq/L) concurrent with high
blood lactate (8 mmol/l). (4) Mild developmental delay
associated with normal brain ultrasound. (5) Failure to
thrive and vomiting. Metabolic workup showed high
urinary lactate and Krebs cycle intermediates. Muscle
biopsy was morphologically normal. Immunohistochem-
ical staining demonstrated focal COX deficiency in 5%
of the fibers. Enzymatic analysis of respiratory chain
complexes revealed mildly reduced activity of all
complexes except for complex II. These results are ex-
pressed as percentage of the mean control values: citrate
synthase, 95%; NADH-ferricyanide reductase, 48%;
NADH-cytochrome C reductase, 40%; succinate dehydro-
genase, 115%; succinate-cytochrome C oxidoreductase,
96%; and cytochrome C oxidase, 57%.3 At 1 year of age
she was suffering from failure to thrive despite feedingn Journal of Human Genetics 88, 193–200, February 11, 2011 195
enriched formula provided via percutaneous gastrostomy
tube, worsening renal failure, slow psychomotor develop-
ment, severe pulmonary hypertension, and diabetes melli-
tus. One month later she died of refractory pulmonary
hypertension.
Analysis of the pedigree suggested an autosomal-reces-
sive disorder, associated with compromised energy produc-
tion, and led to the assumption that this is a defect in
nuclear DNA rather than in mitochondrial DNA (mtDNA).
The enzymatic activity of the mitochondrial respiratory
chain complexes in mitochondria isolated from patients’
muscle specimens were determined by standard spectro-
photometric methods. The activities of complex I, III,
and IV, normalized to control reference values, were
reduced and only complex II activity was relatively
preserved. Because complex II is the only complex that is
encoded solely by the nuclear genome, this pattern sug-
gested a defect in the synthesis of the mtDNA-encoded
proteins. However, the ratio of mtDNA to nuclear DNA
in patient F1:III-1 muscle was found to be within the
normal range (70% of the age-matched control mean),
which excludes mtDNA depletion.
Nuclear-encoded genes are central to a number of
processes pertinent to the synthesis of mtDNA-encoded
proteins (mitochondrial transcription, translation, and
replication machinery) as well as assembly and stability
of the mitochondrial respiratory complexes. The consan-
guinity in family 1 implied that the gene bearing a patho-
genic mutation would be located within a homozygous
identity-by-descent region. We undertook a genome-wide
SNP homozygosity analysis of these two patients, aiming
to identify a candidate gene.
Genomic DNA was extracted from blood samples of
patients, their parents, and control individuals. All experi-
ments involving DNA and cell cultures from patients, as
well as DNA from parents and healthy controls, were per-
formed after obtaining informed consent and were
approved by the Shaare Zedek Medical Center Ethics
Committee (number 78/09) and by the National
Committee for Genetic Studies of the Israeli Ministry of
Health (number 019-2010). Homozygosity mapping of
DNA from patients F1:III-1 and F1:III-6 was performed on
GeneChip Human Mapping 250K Nsp Array from Affyme-
trix. The experiments were performed according to
protocols provided by the manufacturer. Quality control
and data analysis (genotyping) were performed with the
Genotyping Console. The genotypes were then analyzed
with the KinSNP software. The children shared two
homozygous fragments, each one of whom was more
than 2 Mbp in length: 5 Mbp on chromosome 19 (from
39.3 Mbp [rs12611086] to 44.4 Mbp [rs11083515]; total
220 SNPs) and 2.1 Mbp on chromosome 4 (from
67.9 Mbp [rs11131698] to 70.0 Mbp [rs7677996]; total
147 SNPs). These two homozygous loci contained alto-
gether approximately 150 genes.
Molecular diagnostic algorithms for the selection of
candidate genes causing mitochondrial disorders have196 The American Journal of Human Genetics 88, 193–200, Februarybeen formulated recently.4–7 Taking into account these
considerations, we selected the following candidate genes,
all located on chromosome 19, given that their products
are imported into the mitochondria and associated with
energy supply: COX6B1 (MIM 124089), COX7A1 (MIM
123995), MRPS12 (MIM 603021), and SARS2 (MIM
612804). Direct DNA sequencing of all the exons and the
adjacent exon-intron boundaries was carried out and
yielded only one mutation. The single homozygous muta-
tion, c.1169A>G, resulting in p.Asp390Gly, was in exon 13
of SARS2, the gene encoding mitochondrial seryl-tRNA
synthetase (NCBI Reference Sequence: NM_017827.3).
The causative nature of this mutation was substantiated
by the detection of the samemissensemutation in a homo-
zygous fashion in patient F2:II-2, who has an identical
phenotype. The parents of patients F1:III-1, F1:III-6, and
F2:II-2 were tested and, as expected, were found to be
carriers of this mutation (Figure 3). Their four unaffected
siblings were heterozygous for the mutation. Collectively,
this mutation segregates with the disease in these families.
The PolyPhen predictor defines this mutation as probably
damaging. The mutation was absent in 212 chromosomes
derived from healthy unrelated individuals of Palestinian
descent. Targeted screening of this mutation was per-
formed on anonymous DNA samples of individuals from
the same village. This revealed a very high carrier rate of
1:15 (7 out of 103 samples tested).
The eukaryotic mitochondria presumably evolved from
the fusion of an oxidative bacterium with a glycolytic
proto-eukaryotic cell. Its genetic machinery includes
several nonuniversal codons and the translation system
uses 22 tRNAs encoded by mtDNA. Eighteen tRNAs corre-
spond to one amino acid each. Two additional amino acid
residues (leucine and serine) acylate two tRNA isoacceptors
each. A set of 20 aminoacyl-tRNA synthetases (ARSs), each
one corresponding to a single amino acid, is encoded in
the nucleus and the product is imported into the mito-
chondria. Only three ARSs (not including SARS) are found
both in the cytosol and the mitochondria. Aminoacyl-
tRNA synthetases provide the specific attachment of
amino acids to the 30-ends of their cognate tRNA. They
are subdivided into two groups based on their protein
structural characteristics. SARS2 is a homodimeric enzyme
whose catalytic domain is composed of the antiparallel
b sheet architecture with three short conserved motifs,
belonging to the class II ARS. The mutated aspartic acid
residue is positioned at the C-terminal globular domain
and located in the second of eight b-strands that assemble
the active site.8
Mutations in mitochondrial ARSs resulting in decreased
aminoacylation by the corresponding amino acid are ex-
pected to adversely affect mitochondrial translation
systems and lead to derangements in the synthesis of mito-
chondrial proteinsandconsequently inenergy supply.Thus
far, mutations in three mitochondrial ARS-encoding genes
have been found to be pathogenic: DARS2 (MIM 610956),
resulting in leukoencephalopathy with brain stem and11, 2011
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Figure 3. Mutation Analysis of DNA Samples from Patients, Carriers, and Normal Individual and Confirmation of the Conservation
among Species of the Mutated Amino Acid in SARS2
(A) DNA sequence identifying the c.1169A>G mutation in SARS2.
(B) Restriction enzyme analysis with BsaJI: this mutation introduces a restriction site for this enzyme, which results in the digestion of
the 166 bp oligonucleotide into 94 bp and 72 bp fragments.
(C) Multiple sequence alignment of SARS2 in various species with ClustalW program. In red: the amino acid corresponding to the muta-
tion in human DNA c.1169A>G (p.Asp390Gly).spinal cord involvement associated with elevated lactate
concentrations (LBSL; MIM 611105);9 RARS2 (MIM
611524) leading to infantile encephalopathy, predomi-
nantly affecting the cerebellum (MIM 611523);10 and
YARS2 (MIM 610957) manifesting as myopathy, lactic
acidosis, and sideroblastic anemia (MLASA;MIM613561).11
The major determinant of specific recognition by SARS
in prokaryotic, eukaryotic, and archaeal systems is the
characteristic long variable arm of the serine isoacceptors.
Of note, SARS2, which represents the mitochondrial seryl-
tRNA synthetase, provides serine aminoacylation to two
mitochondrial tRNAs. In both of them this elongated
variable arm is absent. In addition, tRNASerAGY lacks the
entire D domain12 whereas the tRNASerUCN is missing
a single nucleotide in the connector between the acceptor
and the D-arm and has an unusual cloverleaf configuration
with an extended anticodon stem13,14 (Figure 4). More-
over, these two tRNAs do not share sequence or structural
similarities.8 It is therefore assumed that the recognition
elements that define the specificity of SARS2 to two isoac-
ceptors are different.15
The impact of structural dissimilarities between the two
mitochondrial serine isoacceptors on the binding and
acylation mechanisms of SARS2 was confirmed, in part,
by the aminoacylation assay of the protein product of
SARS2 containing specific mutations performed by Chim-
naronk et al.8 The authors demonstrated that some
mutants lead to a decrease in activity with respect to one
of the isoacceptors without having any effect on theThe Americasecond one. These experiments confirm the dual-mode
recognition of two substrate tRNAs. Unfortunately, this
analysis does not include mutations in the area of the
SARS2 corresponding to the A2 b-strand, which is relevant
to our cases. In order to evaluate the pathogenic effect of
the c.1169A>G SARS2 mutation on tRNAsSer acylation,
we used EBV-immortalized peripheral lymphocyte cultures
derived from patients. Total RNA was isolated under acidic
conditions in order to preserve aminoacylation and was
resolved on an acidic gel as described by Varshney16 and
modified by Chernyakov.17 Aminoacylated RNAs were
separated by electrophoresis on a 6.5% polyacrylamide
gel containing 8M urea. The aminoacylated tRNAmigrates
slower than its corresponding deacylated species. After
separation, RNA was transferred to a membrane. Specific
tRNAs were visualized with oligonucleotide DNA probes




the 50 end via standard northern blotting techniques
(Figure 5). The signals were quantified, normalized to the
signal of MT-tRNALeu (loading control), and expressed as
a ratio compared to tRNASerAGY or tRNA
Ser
UCN signals in
normal lymphocyte culture. Normalization to probes of
genomic tRNASer and genomic tRNALeu yielded similar
results (data not shown). The amount of total tRNASerAGY
in patient’s cells was reduced to 10%–20% of the control.
The residual pool of this tRNA was nonacylated. In
contrast, the total amount of tRNASerUCN was nearly iden-
tical to the control. We conclude that the c.1169A>G
mutation in SARS2 significantly impairs the ability of then Journal of Human Genetics 88, 193–200, February 11, 2011 197
Figure 4. Comparison of the Secondary
Structures of E. coli tRNASer with Two
Human Mitochondrial tRNAsSer
Human tRNASerAGY (A) and tRNA
Ser
UCN (B)
are shown.enzyme to acylate tRNASerAGY. These data support the
concept that uncharged tRNA undergoes degradation and
that mutations in ARS decrease the amount of not only
the charged product but also of the uncharged substrate.10
Experimental data show that failure of aminoacylation
leads to degradation and decrease in the steady-state levels
of mutated tRNAs.18,19 If we extrapolate these observations
to tRNASerUCN, we can conclude that the level of its acyla-
tion was not significantly decreased. However, because
separation of the charged from the uncharged form of
tRNASerUCN could not be achieved because of similar
mobility of these two species, the possibility that in the
patient’s sample this isoacceptor remained mostly in the
uncharged form cannot be entirely excluded.
We speculate that other pathogenic mutations in SARS2
may result in inhibition of acylation of tRNASerUCN causing
a different phenotype. For instance, sensorineural deafness
has been shown to be caused by mutations in the mito-
chondrial gene encoding tRNASerUCN.
20 However, the
consequences of MT mutations are hardly predictable.
Indeed, mutations in the mitochondrial gene encoding
tRNASerAGY, which theoretically prevent its ability to be
acylated by serine, similar to the effect of the p.Asp390Gly
mutation in SARS2, were reported to result in a completely
different phenotype consisting primarily of a neurological
disease affecting the central nervous system (basal ganglia
and cerebral atrophy) and the proximal muscles.21
The most striking features of the phenotype resulting
from a homozygous missense mutation in SARS2 were
prematurity, progressive renal disease, and primary pulmo-
naryhypertension. Feedingproblems, resulting in failure to
thrive and developmental delay, were also noted without198 The American Journal of Human Genetics 88, 193–200, February 11, 2011obvious morphological alterations in
the brain after brain ultrasound. The
most common renal phenotype
attributed to mitochondrial cyto-
pathy is the Fanconi syndrome. Our
patients presentedwith a tubulopathy
butwithoutperturbations inproximal
tubular functions, which often mani-
fest as glycosuria, phosphaturia,meta-
bolic acidosis, or generalized amino-
aciduria. Reduced energy production
may account for impaired tubular
function especially in the thick
ascending limb of the loop of Henle,
which is known to have a high energy
requirement, primarily needed to
support the Na-K-ATPase cotrans-
porter activity, and is therefore suscep-tible to anoxic damage. Our patients showed features of the
thick ascending limb dysfunction that resemble those
observed in patients treated with excessive doses of loop
diuretics, known to inhibit the luminal Na-K-2Cl cotrans-
porter. They had salt wasting resulting in hyponatremia,
urinary magnesium leak leading to hypomagnesemia, and
decreased concentration capacity associated with polyuria
and significantly elevated blood urea levels dispropor-
tionate to the creatinine concentrations.Markedmetabolic
alkalosis, despite decreasing renal function, may have
resulted from the combination of hypochloremia and
relative volume depletion, a phenomenon known as
contraction alkalosis. The latter may also be responsible
for the hyperuricemia with decreased urinary fractional
excretion of uric acid. The acceptedmechanism underlying
hyperuricemia within the context of pulmonary hyperten-
sion is increased production of uric acid in ischemic/
hypoxic cardiac tissue.22 This would result in normal, if
not increased, fractional excretion of uric acid. The mark-
edly decreased FeUA observed in our patients supports
aprimary renal tubular defect as themain causeofhyperuri-
cemia. The clinical signs of tubulopathy were supported by
the tubular abnormalities observed under electron micros-
copy. The combination of urinary concentration defect,
salt wasting, hyperuricemia, and renal insufficiency was
previously described in two familial cases with a mito-
chondrial point mutation.2 They also shared similar
histological findings. It is quite intriguing that morpholog-
ical alterations were not detected by brain ultrasound
despite the fact that the brain is a tissue with high energy
requirement and that SARS2 mRNA is highly expressed in
this organ.
AB
Figure 5. Quantitative Analysis of tRNASerAGY and tRNA
Ser
UCN
Amino Acylation in EBV-Transformed Lymphocyte Cultures
(A) Northern blot: equal amounts (2 mg) of total RNA purified from
normal and patient-derived lymphocyte lines were separated at
4C on an acidic 6.5% polyacrylamide-7 M urea gel. Hybridization
with 32P-labeled probes for tRNASerAGY and tRNA
Ser
UCN. The blots
were then stripped and rehybridized with probes for MT-tRNALeu.
One representative northern hybridization, out of three experi-
ments, is presented. DA denotes deacylated tRNA.
(B) Histogram presentation of the data from (A). The intensity of
hybridization signals was normalized by the signal of loading
control MT-tRNALeu and is presented as percentage of the signal
of the corresponding probe in the control.When considering the various possible functions of
SARS2, it should be noted that according to all the bioin-
formatic annotations, it could participate in the biosyn-
thesis of selenocysteinyl-tRNA in the mitochondria (see
UniProt, UCSC Browser, GeneCards). We assume that
this process is unlikely to occur, because the human mito-
chondrial genome does not encode selenoproteins and,
furthermore, UGA used by selenocysteinyl-tRNA codes
for tryptophan in the human mitochondrial genome.23
We therefore disregarded this possibility in our experi-
ments.
Quantitative analysis of the northern blot revealed that
the total amount of tRNASerAGY was significantly reduced
to 10%–20% of the control, whereas the acylated form
was undetectable. The subunits of all three MT-encoded
complexes of the respiratory chain contain the AGY
codons, but in varying proportions. 11 out of 13 MT
protein-encoding genes possess these codons and canThe Americatherefore be truncated during expression. Absence of the
charged tRNASerAGY may alter the balance between the
nuclear-encoded and MT-encoded subunits of these
complexes. Given the residual activity of the mutated
SARS2, we speculate that it maintains most tissues above
their necessary threshold but fails to do so in tissues with
high energy requirement. This phenomenon has been
described in patients with neuronal mitochondrial cyto-
pathy resulting from mutations in DARS2, in whom the
overall mitochondrial function in patients’ fibroblasts
and lymphoblasts were seemingly normal in the face of
severe neuronal disease.9 Accordingly, mutations in
SARS2 resulting in a significant decrease of the respiratory
chain activity may be critical for the thick ascending limb,
which has a high density of mitochondria needed to
provide the excessive energy level required for the mainte-
nance of the various transporters. This concept, in addi-
tion to explaining the tissue specificity of the disease,
may also account for the disparity in the activity of the
respiratory complexes in the muscle biopsies of our
patients. Further studies are warranted in order to confirm
this hypothesis.
We describe three infants diagnosed with an uncharac-
terized multisystem fatal mitochondrial cytopathy, which
we named HUPRA syndrome (hyperuricemia, pulmonary
hypertension, renal failure in infancy, and alkalosis). The
genetic basis underlying this recessively inherited clinical
entity is a homozygous founder mutation in SARS2 that
is highly prevalent among the inhabitants of a Palestinian
village. This information will enable the implementation
of targeted screening and the provision of premarital and
prenatal diagnosis to couples at risk. In fact, we have
recently analyzed a chorionic-villus sample derived from
F2:I-1 and found that she carries an unaffected fetus. The
combination of signs of thick ascending limb dysfunction
(primarily hyperuricemia and alkalosis) with progressive
renal failure in infancy should raise the possibility of mito-
chondrial cytopathy.Acknowledgments
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